Developing novel approaches to targeting the “undruggable”
Our Corporate mission
We are a developmental-stage pharmaceutical company that is exploiting novel and powerful approaches to creating, testing and developing compounds that are effective against previously “undruggable” targets. As part of this process, we have developed novel systems for the expression of human proteins and other biologically-active substances in a variety of hosts. We are currently using these systems in the process of drug discovery. Our research process includes, but goes beyond, AI-based modeling, to include high-throughput screening, lead compound optimization, and the testing of suitable drug candidates in a variety of biochemically-based, cell-based and whole-organism models. Located in the greater Boston area, we can draw upon our scientifically-fertile interactions with various academic partners, both locally and world-wide. We are also selectively developing alliances with other pharma companies that can accelerate progress towards joint corporate objectives.
Recent Publications
Bolger, G.B. 2025 PDE4-Selective Inhibition in Chronic Obstructive Pulmonary Disease and Pulmonary Fibrosis: Different Agents or Different Targets? Life - 3889701 Doi: 10.3390/life15101600
https://www.mdpi.com/2075-1729/15/10/1600
Kelly, M. P., Nikolaev, V. O., Gobejishvili, L., Lugnier, C., Hesslinger, C., Nickolaus, P., Kass, D. A., Pereira de Vasconcelos, W., Fischmeister, R., Brocke, S., Epstein, P. M., Piazza, G. A., Keeton, A. B., Zhou, G., Abdel-Halim, M., Abadi, A. H., Baillie, G. S., Giembycz, M. A., Bolger, G., Snyder, G., Tasken, K., Saidu, N. E. B., Schmidt, M., Zaccolo, M., Schermuly, R. T., Ke, H., Cote, R. H., Mohammadi Jouabadi, S. and Roks, A. J. M. 2025 Cyclic nucleotide phosphodiesterases as drug targets. Pharmacol Rev 77: 100042. 2025/03/14.
DOI: 10.1016/j.pharmr.2025.100042
Bolger, G.B. 2024 PDE4 inhibition and enhancement of human memory and cognition. Cell Signal 3: 1-9. 2024.
DOI: https://doi.org/10.46439/signaling.3.048
Bolger, G. B. 2023 Therapeutic Targets and Precision Medicine in COPD: Inflammation, Ion Channels, Both, or Neither? Int J Mol Sci 24: 2023/12/23.
DOI: 10.3390/ijms242417363
Bolger, G. B. 2022 The cAMP-signaling cancers: Clinically-divergent disorders with a common central pathway. Front Endocrinol (Lausanne) 13: 1024423. 2022/11/01.
DOI: 10.3389/fendo.2022.1024423
Bolger, G. B. 2021 The PDE-Opathies: Diverse Phenotypes Produced by a Functionally Related Multigene Family. Trends Genet 37: 669-681 2021/04/10.
DOI: 10.1016/j.tig.2021.03.002